Skip to Main content Skip to Navigation
Journal articles

Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?

Abstract : Abstract Background Guidelines suggest that patients discontinue Clopidogrel at least 5 days prior to coronary artery bypass grafting (CABG). Those with acute coronary syndrome (ACS) are at high risk for myocardial infarction (MI) if not treated with dual antiplatelet therapy (DAPT). We sought to assess pre and post-operative outcomes of patients maintained on Clopidogrel and aspirin up to the time of surgery and compare them with those on aspirin alone. Methods From the cardiac surgery database, 240 patients were retrospectively registered between January and May 2017. There were 126 patients with ACS who underwent CABG on DAPT (Clopidogrel group [CG]) and 114 patients who underwent elective CABG on aspirin alone (control). The CG received intraoperative prophylactic platelet transfusion (PPT). Demographics, comorbidities, and laboratory data were prospectively entered at the time of surgery and were subsequently retrieved for analysis. Per and postoperative findings were identified and compared between both groups. Results The cohort consisted of 240 patients (mean age 61 years, 81.3% were male, SD ± 9.58). Patients in the CG were younger (Median 57 vs. 63, P -value 0.001), and with male predominance (86% versus 75%, P -value 0.028). In addition, they had less prevalence for diabetes and renal failure as compared to control ( P -values 0.003, and 0.005, respectively). There were no significant differences between both groups in number of vessels grafts, duration of on-pump and aortic clamp. Hematologic laboratory data had also similar baseline values. The CG had similar bleeding rate, redo surgery and in-hospital death ( P -values non-significant), however more infection and total hospital stay as compared to control ( p -values 0.048 and 0.001). Conclusion Patients who are at increased risk for MI can be maintained on DAPT up to the time of CABG because surgery is safe when patients are offered PPT.
Complete list of metadata

https://hal-cnam.archives-ouvertes.fr/hal-03202416
Contributor : Genane Youness <>
Submitted on : Monday, April 19, 2021 - 8:19:19 PM
Last modification on : Wednesday, April 21, 2021 - 3:16:30 AM

Links full text

Identifiers

Citation

Fida Charif, Righab Hamdan, Genane Youness, Ali El Zein, Mohamad Issa, et al.. Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?. Journal of Cardiothoracic Surgery, BioMed Central, 2019, 14 (1), ⟨10.1186/s13019-019-1028-2⟩. ⟨hal-03202416⟩

Share

Metrics

Record views

36